Last reviewed · How we verify
Chirhostim (Secretin Human)
Chirhostim works by binding to the secretin receptor, mimicking the natural hormone secretin to stimulate pancreatic function.
Chirhostim (Secretin Human) is a small molecule hormone developed by CHIRHOCLIN, targeting the secretin receptor. It is classified as a secretin-class hormone and was FDA-approved in 2002 for Secretin Stimulation Testing. As a patented product, its commercial status is proprietary. Key safety considerations include its half-life of 2.41 hours. Chirhostim is used to diagnose pancreatic function.
At a glance
| Generic name | Secretin Human |
|---|---|
| Sponsor | Chirhoclin |
| Drug class | Secretin-class Hormone |
| Target | Secretin receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 2002 |
Mechanism of action
Mechanism of Action. 12.1 Mechanism of ActionThe primary action of ChiRhoStim (R) is to stimulate pancreatic ductal cells to secrete pancreas fluid in large volumes that contain bicarbonate. Secretin is hormone that is normally released from the duodenum upon exposure of the proximal intestinal lumen to gastric acid, fatty acids and amino acids. Secretin is released from enterochromaffin cells in the intestinal mucosa. Secretin receptors have been identified in the pancreas, stomach, liver, colon and other tissues. When secretin binds to secretin receptors on pancreatic duct cells it opens cystic fibrosis transmembrane conductance regulator (CFTR) channels, leading to secretion of bicarbonate-rich-pancreatic fluid. Secretin may also work through vagal-vagal neural pathways since stimulation of the efferent vagus nerve stimulates bicarbonate secretion and atropine blocks secretin-stimulated pancreatic secretion.
Approved indications
- Secretin Stimulation Testing
Common side effects
- Nausea
- Vomiting
- Flushing
- Upset stomach
Key clinical trials
- Imaging Biomarkers of Pancreatic Function and Disease (PHASE4)
- Secretin in Refeeding
- A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects (PHASE4)
- Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
- The Cancer of the Pancreas Screening-5 CAPS5)Study (PHASE3)
- The Effects of Bariatric Surgeries on Glucose Metabolism (EARLY_PHASE1)
- The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
- The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chirhostim CI brief — competitive landscape report
- Chirhostim updates RSS · CI watch RSS
- Chirhoclin portfolio CI